Can Fite Biopharma (CANF)

Executive Summary

Can Fite Biopharma is a clinical-stage biopharmaceutical company developing orally available small molecule drugs targeting the A3 adenosine receptor (A3AR) for inflammatory diseases and cancer. Its lead candidate, piclidenoson (CF101), is in Phase 3 for plaque psoriasis, with a global trial initiated in 2025. Namodenoson (CF102) is in Phase 3 for hepatocellular carcinoma (HCC) and Phase 2 for pancreatic cancer. The company also has early-stage programs in NASH. Despite a robust scientific rationale and multiple completed trials, Can Fite has faced clinical setbacks and its market capitalization is under $10 million, reflecting high risk. Key upcoming data readouts could provide significant de-risking events.

Upcoming Catalysts (preview)

• Q4 2026Namodenoson Phase 3 HCC top-line data35% success
• Q1 2027Namodenoson Phase 2 pancreatic cancer top-line data30% success